DYGN appears to be under accumulation for the past week. A lot of shares traded on no news yesterday.. Could be to just being in Biotech arena or a play off ENMD. Below I posted Old news but if there is positive news on the horizon in regards to this it would be a nice catch. I have no idea why the accumulation for the past 5-6days.
CAMBRIDGE, Mass.--(BW HealthWire)--Feb. 18, 1998--DynaGen Inc.
(NASDAQ:DYGN)(BSE:DYG) today announced that it has received a Notice of Allowance
from the U.S. Patent Office for its patent application covering the use of its immunomodulator
(ImmuDyn(TM)) in the treatment of HIV/AIDS. ImmuDyn is a proprietary lipid preparation
that has shown promise in overseas clinical studies in the treatment of HIV infection. In human
clinical trials, ImmuDyn has demonstrated an acceptable safety profile with no significant
side-effects.
During the past two years, DynaGen has evaluated ImmuDyn in other conditions such as
immune thrombocytopenic purpura (ITP), and autoimmune disease in which platelets are
destroyed by the body's own immune system. The results of ITP human trials are equally
encouraging. DynaGen is focusing its research efforts on ImmuDyn in the treatment of ITP, for
which it has obtained orphan drug status from the FDA. DynaGen has formed a subsidiary,
Apex Pharmaceuticals Inc., which will be independently funded to further develop and
commercialize ImmuDyn.
"This patent will secure for DynaGen a strong proprietary foundation in the HIV arena for our
ImmuDyn product," said Michael Sorell, M.D., director of DynaGen. "Although our initial
focus is for the use of ImmuDyn in ITP, we have plans to pursue its application in other
immune function disorders including HIV," he added.
DynaGen has filed patent applications for ImmuDyn for the treatment of ITP as well as for
neutropenia associated with cancer chemotherapy.
DynaGen Inc. is a healthcare company founded in 1988. DynaGen's other major business
activities include the BioLocator(TM) technology for the efficient and accurate localization and
tracking of breast tumors, and the development of its multisource pharmaceutical business
through its two subsidiaries, Able Laboratories, Inc. of South Plainfield, N.J., which
manufactures tablets and suppositories, and Superior Pharmaceutical Company of Cincinnati,
Ohio, a distributor of generic drugs with annual revenues in excess of $25 million.
Any statements which are not historical facts contained in this press release are
forward-looking statements that involve risks and uncertainties. Please refer to the risk factors
identified in the company's recent report on Form 10-K, including those relating to
commercialization of products and the company's limited manufacturing and marketing
experience. There can be no assurance that the anticipated benefits from the issuance of such
a patent will be realized. |
